相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
Lydia Meder et al.
CANCER RESEARCH (2018)
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
Lei Zhang et al.
NEURO-ONCOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
Priyanka C. Iyer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
Aleksandra Popovic et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
An early history of T cell-mediated cytotoxicity
Pierre Golstein et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Regulatory mechanisms in T cell receptor signalling
Guillaume Gaud et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
First-line therapy in advanced Renal Cell Carcinoma A randomized, open-label Phase-III-Study Evaluating the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib compared to Sunitinib Monotherapy as First-Line Treatment for locally advanced or metastatic Renal Cell Carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO
H. Rexer et al.
UROLOGE (2017)
First-line therapy in advanced Renal Cell Carcinoma A randomized, open-label Phase-III-Study Evaluating the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib compared to Sunitinib Monotherapy as First-Line Treatment for locally advanced or metastatic Renal Cell Carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO
H. Rexer et al.
UROLOGE (2017)
Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
Xinqi Wu et al.
CANCER IMMUNOLOGY RESEARCH (2017)
High Endothelial Venules and Other Blood Vessels: Critical Regulators of Lymphoid Organ Development and Function
Ann Ager
FRONTIERS IN IMMUNOLOGY (2017)
De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors
Anna Johansson-Percival et al.
NATURE IMMUNOLOGY (2017)
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Valentina Comunanza et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2017)
Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
Florence T. H. Wu et al.
CANCER RESEARCH (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
Luuk van Hooren et al.
ONCOTARGET (2016)
VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
Xinqi Wu et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention
Catherine Sautes-Fridman et al.
FRONTIERS IN IMMUNOLOGY (2016)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation
Hua Huang et al.
FASEB JOURNAL (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Intertwined regulation of angiogenesis and immunity by myeloid cells
Lee B. Rivera et al.
TRENDS IN IMMUNOLOGY (2015)
Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data
Patrick A. Ott et al.
FRONTIERS IN ONCOLOGY (2015)
Tumour Angiogenesis and Angiogenic Inhibitors: A Review
Lalita Yadav et al.
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH (2015)
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Naveen S. Vasudev et al.
ANGIOGENESIS (2014)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Control of the adaptive immune response by tumor vasculature
Laetitia Mauge et al.
FRONTIERS IN ONCOLOGY (2014)
A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis
Massimo Masiero et al.
CANCER CELL (2013)
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo
S. Yasuda et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Jonathan Welti et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
An evolving new paradigm: endothelial cells - conditional innate immune cells
Jietang Mai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nitric Oxide-Producing Myeloid-Derived Suppressor Cells Inhibit Vascular E-Selectin Expression in Human Squamous Cell Carcinomas
Ahmed E. Gehad et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization
Lothar C. Dieterich et al.
JOURNAL OF PATHOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Endothelial Cell Heterogeneity
William C. Aird
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Egfl7 Promotes Tumor Escape from Immunity by Repressing Endothelial Cell Activation
Suzanne Delfortrie et al.
CANCER RESEARCH (2011)
Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling
Tereza Cindrova-Davies et al.
CARDIOVASCULAR RESEARCH (2011)
Enhancement of T-cell-Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer
Ruud P. M. Dings et al.
CLINICAL CANCER RESEARCH (2011)
Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications
Katrien De Bock et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2011)
Stem cells in tumor angiogenesis
Shentong Fang et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2011)
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
Katrien De Bock et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer
Elise Langenkamp et al.
CELL AND TISSUE RESEARCH (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer
Hendrik-Tobias Arkenau et al.
ONCOLOGY (2009)
TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype
Richard C. A. Sainson et al.
BLOOD (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
Bevacizumab for the treatment of advanced non-small-cell lung cancer
Christian Manegold
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells
Rachael A. Clark et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Ronald J. Buckanovich et al.
NATURE MEDICINE (2008)
Tumors skew endothelial cells to disrupt NK cell, T-cell and macrophage functions
Jennifer K. Mulligan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Evolving functions of endothelial cells in inflammation
Jordan S. Pober et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Hypoxia: A key regulator of angiogenesis in cancer
Debbie Liao et al.
CANCER AND METASTASIS REVIEWS (2007)
Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: Identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy
Caroline Bouzin et al.
JOURNAL OF IMMUNOLOGY (2007)
Force as a facilitator of integrin conformational changes during leukocyte arrest on blood vessels and antigen-presenting cells
Ronen Alon et al.
IMMUNITY (2007)
Anti-angiogenic therapies in cancer: achievements and open questions
Curzio Ruegg et al.
BULLETIN DU CANCER (2007)
Getting to the site of inflammation: the leukocyte adhesion cascade updated
Klaus Ley et al.
NATURE REVIEWS IMMUNOLOGY (2007)
VEGF receptor signalling - in control of vascular function
AK Olsson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease
S Goebel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors
Anita E. M. Dirkx et al.
FASEB JOURNAL (2006)
Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1α complex
F Miller et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Cellular abnormalities of blood vessels as targets in cancer
P Baluk et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Tumorigenesis and the angiogenic switch
G Bergers et al.
NATURE REVIEWS CANCER (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κB activation in endothelial cells
I Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
